Gan&Lee is a high-tech biopharmaceutical enterprise integrating research
Gan & Lee Pharmaceutical Co., Ltd. was established in 1998, is a high-tech biopharmaceutical enterprise integrating research, development, production and sales. The company is a leading company at home and abroad in the development, research and production of biosynthetic human insulin and its analogs, and is a professional company focusing on biosynthetic human insulin analogs.
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
Zhaolihong, former member of the Party committee and vice president of Agricultural Bank of China Hebei Branch, was "double opened"
Liaoning Province held a working meeting to promote the listing of enterprises and launched the doubling plan for the listing of enterprises
Pioneer fund welcomes the new general manager and the executive deputy general manager will no longer act as the general manager
2022 China AI Health 30 Report
Haipurui: it plans to publicly issue corporate bonds of no more than RMB 1.5 billion to professional investors
Humon shares: the 2021 ESOP has not yet started to purchase the company's shares
Stellar Technology: 34.6 million shares pledged and extended by the controlling shareholder
Ganli pharmaceutical won the bid for centralized procurement of insulin glargine injection
Special national collection of insulin: Ganli pharmaceutical Ganjing and asparagus insulin all reported the lowest prices: 48.71 yuan and 19.98 yuan
Robin Li: Baidu has become the world's largest automated driving service provider.
Urban investment holding: the newly signed amount of real estate projects in the third quarter was about 304.3 million yuan
HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D
Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.
Apr 23, 2023 12:20 PM
Xin Guobin: accelerate the promotion of robots such as family services, education and entertainment
Huitai medical: net profit in the first half of the year increased by 186.24% year-on-year
During the 14th Five Year Plan period, China will restore 230 million mu of degraded grassland
Pharmaceutical and biological stocks fell sharply in early trading